Salvati V M, Mazzarella G, Gianfrani C, Levings M K, Stefanile R, De Giulio B, Iaquinto G, Giardullo N, Auricchio S, Roncarolo M G, Troncone R
Department of Paediatrics, University Federico II, Via Pansini, No 5, 80131 Naples, Italy.
Gut. 2005 Jan;54(1):46-53. doi: 10.1136/gut.2003.023150.
BACKGROUND: Enteropathy in coeliac disease (CD) is sustained by a gliadin specific Th1 response. Interleukin (IL)-10 can downregulate Th1 immune responses. AIM: We investigated the ability of recombinant human (rh) IL-10 to suppress gliadin induced Th1 response. PATIENTS AND METHODS: IL-10 RNA transcripts were analysed by competitive reverse transcription-polymerase chain reaction in duodenal biopsies from untreated and treated CD patients, non-coeliac enteropathies (NCE), and controls. CD biopsies were cultured with a peptic-tryptic digest of gliadin with or without rhIL-10. The proportion of CD80+ and CD25+ cells in the lamina propria, epithelial expression of Fas, intraepithelial infiltration of CD3+ cells, as well as cytokine synthesis (interferon gamma (IFN-gamma) and IL-2) were measured. Short term T cell lines (TCLs) obtained from treated CD biopsies cultured with gliadin with or without rhIL-10 were analysed by ELISPOT for gliadin specific production of IFN-gamma. RESULTS: In untreated CD and NCE, IL-10 RNA transcripts were significantly upregulated. In ex vivo organ cultures, rhIL-10 downregulated gliadin induced cytokine synthesis, inhibited intraepithelial migration of CD3+ cells, and reduced the proportion of lamina propria CD25+ and CD80+ cells whereas it did not interfere with epithelial Fas expression. In short term TCLs, rhIL-10 abrogated the IFN-gamma response to gliadin. CONCLUSIONS: rhIL-10 suppresses gliadin specific T cell activation. It may interfere with the antigen presenting capacity of lamina propria mononuclear cells as it reduces the expression of CD80. Interestingly, rhIL-10 also induces a long term hyporesponsiveness of gliadin specific mucosal T cells. These results offer new perspectives for therapeutic strategies in coeliac patients based on immune modulation by IL-10.
背景:乳糜泻(CD)中的肠病由麦醇溶蛋白特异性Th1反应维持。白细胞介素(IL)-10可下调Th1免疫反应。 目的:我们研究了重组人(rh)IL-10抑制麦醇溶蛋白诱导的Th1反应的能力。 患者和方法:通过竞争性逆转录-聚合酶链反应分析未经治疗和治疗后的CD患者、非乳糜泻性肠病(NCE)患者及对照者十二指肠活检组织中的IL-10 RNA转录本。将CD活检组织与含或不含rhIL-10的麦醇溶蛋白胰蛋白酶消化物一起培养。检测固有层中CD80+和CD25+细胞的比例、Fas的上皮表达、CD3+细胞的上皮内浸润以及细胞因子合成(干扰素γ(IFN-γ)和IL-2)。对用含或不含rhIL-10的麦醇溶蛋白培养的治疗后CD活检组织获得的短期T细胞系(TCLs)进行ELISPOT分析,以检测麦醇溶蛋白特异性IFN-γ的产生。 结果:在未经治疗的CD和NCE中,IL-10 RNA转录本显著上调。在体外器官培养中,rhIL-10下调麦醇溶蛋白诱导的细胞因子合成,抑制CD3+细胞的上皮内迁移,并降低固有层CD25+和CD80+细胞的比例,而不影响上皮Fas表达。在短期TCLs中,rhIL-10消除了对麦醇溶蛋白的IFN-γ反应。 结论:rhIL-10抑制麦醇溶蛋白特异性T细胞活化。它可能通过降低CD80的表达来干扰固有层单核细胞的抗原呈递能力。有趣的是,rhIL-10还诱导麦醇溶蛋白特异性黏膜T细胞产生长期低反应性。这些结果为基于IL-10免疫调节的乳糜泻患者治疗策略提供了新的视角。
Scand J Gastroenterol. 2011-10
Nutrients. 2024-7-11
Clin Immunol. 2024-3
Int J Mol Sci. 2023-9-22
Adv Exp Med Biol. 2021
Iran Biomed J. 2020-5
Clin Exp Immunol. 2019-10-1
World J Gastrointest Pathophysiol. 2017-5-15
Immunol Rev. 2001-8
Gastroenterology. 2000-7
J Immunol. 1999-7-1
Chem Immunol. 1998